Citius Pharmaceuticals, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Citius Pharmaceuticals, Inc. increased its beneficial ownership in Citius Oncology, Inc. to 77.9% following a registered direct offering.
NASDAQ
Citius Pharmaceuticals, Inc.'s beneficial ownership in Citius Oncology, Inc. decreased to 79.1% following a registered direct offering by the subsidiary.
NASDAQ
SCHEDULE: Citius Pharmaceuticals Retains Dominant Stake in Citius Oncology Following Public Offering
Citius Pharmaceuticals, Inc. maintains an 84.3% beneficial ownership in Citius Oncology, Inc. after Citius Oncology's recent public offering of common shares.